Table 2.
Patients (n = 45) | Controls (n = 18) | Pb | ||||
---|---|---|---|---|---|---|
Baseline | Follow-up | Mean difference | Pa | |||
TSH (mIU/L) | 21.89 ± 35.04 | 2.11 ± 1.84 | <0.001 | 1.74 ± 0.98 | ||
FT4 (pmol/L) | 14.00 ± 5.01 | 18.10 ± 3.25 | <0.001 | 14.47 ± 1.68 | ||
8-oxoGuo (nmol/mmol Cr) | 1.63 (1.49–1.78) | 1.67 (1.53–1.83) | 0.97 (0.91–1.04) | 0.39 | 1.23 (1.07–1.42) | <0.001 |
8-oxodG (nmol/mmol Cr) | 1.28 (1.14–1.44) | 1.32 (1.18–1.48) | 0.97 (0.88–1.06) | 0.47 | 1.04 (0.88–1.23) | 0.03 |
aPaired t-test comparing hypothyroid participants at baseline and follow-up; bIndependent t-test comparing oxidative stress markers in hypothyroid participants at follow-up with control subjects.
8-oxoGuo, 8-oxo-7,8-dihydroguanosine; 8-oxodG, 8-oxo-7,8-dihydro-2′-deoxyguanosine; Cr, creatinine; FT4, free thyroxine; TSH, thyrotropin.